199| ~29:43A- | 85A
human blood cell counts: decreases the hematocrit (HCT) and lymphoc~es (LYM): increases platelets ePLT) and polymorphonuclear leukocyte.,, IPMN); and indirectly increases cosinophi|s ~EOS). It is generated by monocytes (MONL Fifteen schizophrenics had CBCs done prior to CLZ administration ~ after being on CLZ for 4 and 6 weeks. Analyses were done by paired t-tests comparing values after 4 and 6 weeks w i ~ baseline. IL-Ib and CLZ cell effect patterns appear to match.
IL- ! b effect CLZ 4 weeks CLZ 6 weeks
dec - 4c~ - 6~'
dec - 5~ - 20c~~
inc + I~ + |0~ ~
iac + 4~ + 30%~
MON ~ + |7~ +~
EOS sl i ~ + 5t% ~ - ~6~ ~
= p < 0.05. b = p < 0.02. ' -- p < 0OI, ~ = ~.me data rmssmg Direct studies on IL-Ib induction by CLZ may be warranted.
THE EFFECTS OF GENDER ON NEUROPSYCHOLOGIC/~:. FUNCTIONS IN SCHIZOPHRENIA Dennis Deptula, Ph.D., Laura Read, Ph.D., Rajkumar Singh, M.D., Trudye Galowin, M.A., Nunzio Pomara, M.D. Nathar, S. Kiine Institute for Ps3:chiatric Research. Orangeburg, N.Y. 10962. it has recently been reported that male, but not female schizophrenics g¢ ~ l y show enlarged ventricles relative to controls on CT and MRI. Given that ventricutar enlargement has been associated with neuropsychological impairment in schizophrenia, it is of interest to assess whether male schizophrenics also have more neuropsychological deficits than female patients° To address this issue, 39 female and 29 male schizophrenic inpatients (DSM-II!-R) without a history of mental retardation, substance abuse, or neurological disorders were administered a cognitive test bakery. Male schizophreriics performed significantly poorer on the Folstein Mini-Mental State Exam (males: mean = 19.07 [ m 7.4]: females: mean = 22.2 [ ± 5.3]; p = 0.05) and on the Wechsler Memory Scale with ma~es having both a lower Memory Quotient tmales: mean = 66.7 [ ± 17.3]; females: mean = 77.7 [ _ | 6 . 7 | ; p = 0.01) and a lower raw s~or~ (males: mean = 2 i . 4 [ ± !:4.31..: females; mean = 27.9 [ + 10.8]; p = 0.04). Males exhibited greater i m ~ n t than females despite the fact thin anales were significantly younger (p = 0.01). Moreover the percentage of patients receiving psychotropic medication was approxh~a~!y equal in both male (69%) and female (74%) groups. Previous investigators have noted that many poor prognostic feat'm--e~.Lncluding CNS structural abnormalities, poor response to neuroleptics, and negative symptoms are more prominent in m ~ e ~hizon h r ~ n l t . c t h a n [email protected]
('~nr ti~lta c n o o a c ~ l h a t n o t t r n n g v c ' h n l c l o ' i c ' a | i r r m a i r m e n t m a y h e a n o t h e r t,m~r prognc~tic feature that is more pronounced in male schizophrenics.
FAMOTIDINE, A HISTAMINE H2.-RECEPTOR ANTAGONIST, AND NEGATIVE SYMPTOMS OF SCHIZOPHRENIA Rami Kaminski M.D., Thomas Moriarty, Ph.D., Dennis Wolf, M.D., Deborah Culliton, M.A., John Bodine, M.D., Michael Davidson, M.D., Kenneth L. Davis, M.D. Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029. There is growing awareness that negative symptoms of schizophrenia (i.e., anhedonia, emotional withdrawal, amotivation, and blunting of affect) may represent a distinct pathophysiological cluster. Indirect evidence suggests that dopaminergic, and possibly serotonergic, abnormalities in the CNS modulate the positive symptoms of schizophrenia. However, the factors affecting negative symptoms r e ~ obscm'e. Further, neuroleptic medications, often effective in the treatment of positive symptoms, show at best only marginal effects in a~leliorating negative symptoms once the acute exacerbation has subsided. We have previously